Suma Krishnan, President, R&D, 10% Owner at Krystal Biotech, Inc. (KRYS), sold 25,000 shares at $300.75 ($7.7M) on 2026-06-04, disclosed to the SEC on 2026-06-05.
Scheduled sale ($7.7M) by President, R&D, 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $300.75 | 320 | $96K | 1.2% |
| 2 | $302.25 | 593 | $179K | 2.3% |
| 3 | $303.17 | 247 | $75K | 1.0% |
| 4 | $304.89 | 400 | $122K | 1.6% |
| 5 | $305.87 | 480 | $147K | 1.9% |
| 6 | $307.09 | 1,348 |
| $414K |
| 5.4% |
| 7 | $307.81 | 12,729 | $3.9M | 50.9% |
| 8 | $308.89 | 3,803 | $1.2M | 15.3% |
| 9 | $309.95 | 2,801 | $868K | 11.3% |
| 10 | $310.94 | 2,039 | $634K | 8.2% |
| 11 | $311.65 | 240 | $75K | 1.0% |
| Total | $308.11 avg | 25,000 | $7.7M | 100% |
| Filing → |
| KRYS | SELL | 2025-12-05 | $20.9M | — | Filing → |
| KRYS | SELL | 2025-07-16 | $10.1M | — | Filing → |
| KRYS | SELL | 2025-07-11 | $4.0M | — | Filing → |